"Drugs, Investigational" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
| Descriptor ID |
D015507
|
| MeSH Number(s) |
D26.371
|
| Concept/Terms |
Drugs, Investigational- Drugs, Investigational
- Investigational New Drugs
- Drugs, Investigational New
- New Drugs, Investigational
- Investigational Drugs
|
Below are MeSH descriptors whose meaning is more general than "Drugs, Investigational".
Below are MeSH descriptors whose meaning is more specific than "Drugs, Investigational".
This graph shows the total number of publications written about "Drugs, Investigational" by people in this website by year, and whether "Drugs, Investigational" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 3 | 0 | 3 |
| 2007 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 16 | 8 | 24 |
| 2018 | 11 | 7 | 18 |
| 2019 | 9 | 4 | 13 |
| 2020 | 3 | 3 | 6 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drugs, Investigational" by people in Profiles.
-
Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Ann Med. 2021 12; 53(1):318-334.
-
When innovation outpaces regulations: The legal challenges for direct-to-patient supply of investigational medicinal products. Br J Clin Pharmacol. 2022 03; 88(3):1115-1142.
-
Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs. Drug Res (Stuttg). 2021 Apr; 71(4):173-179.
-
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerg Med. 2021 03; 16(2):281-308.
-
Ongoing trials on COVID-19 treatments: please, don't forget Venous Thromboembolism! J Thromb Thrombolysis. 2021 May; 51(4):1170-1171.
-
Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. Int J Risk Saf Med. 2021; 32(1):3-17.
-
Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach. Spectrochim Acta A Mol Biomol Spectrosc. 2021 Apr 15; 251:119388.
-
Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19. Clin Pharmacol Ther. 2021 Jul; 110(1):26-28.
-
Experience of conducting clinical trials of investigational medicinal products during a respiratory virus pandemic: Lessons learnt from COVID-19. Clin Trials. 2021 04; 18(2):260-262.
-
Scientists criticize use of unproven COVID drugs in India. Nature. 2020 11; 587(7833):187-188.